drugset / Trial / NCT05550207

Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

NCT05550207

Phase 3 Completed 100 enrolled Axsome Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.

Timeline

Start
2022-08-31
Primary completion
2024-11-27
Completion
2024-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule Oral
Subject rizatriptan Unknown Oral

Indications